Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Outlook Therapeutics CEO Bob Jahr recently participated in the Virtual Investor “Why Now” on-demand conference, with the webcast now available for viewing. During the presentation, Jahr discussed the company's transition to a commercial-stage entity following the FDA approval of LYTENAVA for wet AMD in July 2026. He emphasized the opportunity to bring the only FDA-approved ophthalmic formulation of bevacizumab to the U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.